Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination.

Non Small Cell Lung Cancer Clinical Trial

— Iscador  

Official title:

Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination: Randomized Phase II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00516022
• Other study ID #: Mistletoe.ctil
• Status: Completed
• Phase: Phase 2
• First received: August 13, 2007
• Last updated: September 26, 2011
• Start date: April 2007
• Est. completion date: May 2011

Study information

• Verified date: September 2011
• Source: Rambam Health Care Campus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Mistletoe extract is one of the most common complementary treatments used in Europe. Recent basic studies reported tumor response and survival prolongation in number of treatments with Mistletoe preparations. There are evidence based data for using this drug as side effect reducer when use in combination with chemotherapy regimen treatment. Other clinical data, although not well based is that complementary treatment when used in combination with the common oncology treatment has tumor response effect. Combinations with platinum compound and a third generation cytotoxic agent have been accepted as 'standard of care' for patients with advanced NSCLC. The combination of platinum compound and one of the new agents are associated with response rates of 30-40% and a median survival of 8-11 months for advanced NSCLC patients with good performance status.

Study objective: Improvement in QOL, Improvement in the toxicity profile of the chemotherapy treatment.

Description:

The study design is to include 90 subjects. All subjects are treated with the common chemotherapy treatment. 50 percent will be treated with Iscador as combination with their common chemotherapy regimen. Common chemotherapy regimen used for NSCLC: Carboplatin and Gemcitabine. All study participants will receive this same chemotherapy regimen. This chemotherapy treatment is given every 3 weeks for up to 6 treatment cycles. The first day of the first treatment cycle, the combination of both Carboplatin and Gemcitabine will be administered. After a week (day 8 of treatment cycle) only Gemcitabine will be administered. Drugs would be calculated according to patient's body mass, renal function and general appearance. Once the patient signed Informed Consent he is assigned randomly to be treated with/without the injections of Mistletoe (called "Iscador"). Patient will receive the study medication (Iscador) as an intravenous injection that can be self injected or injected by any other of the family. Injections would be administered with low dose at the first week of the first treatment cycle and then, dose would be escalated, so as to check high sensitivity to the drug. Dosage would include: 2 injections of 0.1 mg, 2 injections of 0.1 mg and 2 injections of 1 mg. After that, treatment would continue with dosage of 10 g once every 2 days.

Patients from both treatment arms would be asked to fill-out QOL questionnaires at every treatment cycle and at follow-up visit after.

Study Primary Objectives:

1. Improvement in QOL

2. Improvement in the toxicity profile of the chemotherapy treatment

Secondary Objectives:

1. Improvement in time to tumor progression (TTP) and survival.

2. Safety profile of mistletoe extract with combination of chemotherapy treatment

This is a single center study, randomized phase II, with patients with advanced NSCLC treated with carboplatin/gemcitabine chemotherapy combination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 79
• Est. completion date: May 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age above 18 years

2. Histology proven of NSCLC

3. Stage IIIB or IV (TNM classification)

4. Performance status < 2 (ECOG classification

5. Measurable disease with one or more disease sites measured by computed tomography (CT)

6. Life expectancy of more than 12 weeks.

7. Treatment combination of gemcitabine/carboplatin (GC)

8. Sign of written informed consent -

Exclusion Criteria:

1. Prior chemotherapy

2. Prior radiation- allowed as long as the treatment was not targeted only site of measurable disease and given more than 3 weeks before entry the trial.

3. Central nervous system metastases

4. Hypercalcemia

5. Other life threatening medical conditions

6. Patients not able to comply with s.c. injections

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Mistletoe extract
The drug will be administered 3 times a week at home.

Locations

Country	Name	City	State
Israel	Rambam Medical Center	Haifa

Sponsors (2)

Lead Sponsor	Collaborator
Rambam Health Care Campus	Weleda AG

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality Of Life	To check the effect of the treatment(or lack of it) on the quality of life of the patients enrolled to the trial.	During the trial	No
Primary	Improvement in QOL. Improvement in the toxicity profile of the chemotherapy treatment	To check on the difference in QoL of all patients.	During all the trial	Yes
Secondary	Objective Response	The patients are asked to answer questions and the doctor will check blood works resolts.	During all the duration of the trial	No
Secondary	Improvement in time to tumor progression (TTP) and survival Safety profile of mistletoe extract with combination of chemotherapy treatment	Looking out for difference in toxicity profile of all patients	During duration of all the trial	Yes